Therapy Areas: Infectious Diseases
USPTO Grants Immunexpress Patent Allowance for Biomarker Quantification Technology
30 July 2018 - - Seattle, Washington-based molecular diagnostic company Immunexpress, Inc. has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for US Patent Application No. 15/160749, "Validating biomarker measurement," which relates to methods used in quantification of biomarkers of its SeptiCyte technology, the company said.
This patent application protects methods used in quantifying biomarker levels in whole blood samples, adding to the current Immunexpress portfolio of 14 patent families, to date of which three have been granted in the US.
Immunexpress has been an early innovator in developing whole-blood, host gene expression biomarkers for differentiating systemic inflammatory conditions caused by infectious and non-infectious agents, resulting in the FDA clearance for SeptiCyte LAB in early 2017.
Immunexpress is committed to improving outcomes for patients suspected of sepsis.
The company's SeptiCyte technology rapidly quantifies, directly from whole blood, specific molecular markers from the patient's own immune system the 'host response'. Its pipeline includes several assays for readily available instruments, including random access, point-of-care and sample-to-answer.
Login
Username:

Password: